- Home
- NIE vs DNA Comparison
NIE vs DNA Comparison
Compare NIE & DNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NIE
- DNA
- Stock Information
- Founded
- NIE 2007
- DNA 2008
- Country
- NIE United States
- DNA United States
- Employees
- NIE N/A
- DNA N/A
- Industry
- NIE Investment Managers
- DNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NIE Finance
- DNA Health Care
- Exchange
- NIE Nasdaq
- DNA Nasdaq
- Market Cap
- NIE 660.9M
- DNA 658.5M
- IPO Year
- NIE N/A
- DNA N/A
- Fundamental
- Price
- NIE $23.94
- DNA $10.24
- Analyst Decision
- NIE
- DNA Sell
- Analyst Count
- NIE 0
- DNA 3
- Target Price
- NIE N/A
- DNA $9.67
- AVG Volume (30 Days)
- NIE 70.5K
- DNA 1.6M
- Earning Date
- NIE 01-01-0001
- DNA 08-07-2025
- Dividend Yield
- NIE 9.04%
- DNA N/A
- EPS Growth
- NIE N/A
- DNA N/A
- EPS
- NIE N/A
- DNA N/A
- Revenue
- NIE N/A
- DNA $237,417,000.00
- Revenue This Year
- NIE N/A
- DNA N/A
- Revenue Next Year
- NIE N/A
- DNA $15.91
- P/E Ratio
- NIE N/A
- DNA N/A
- Revenue Growth
- NIE N/A
- DNA 13.76
- 52 Week Low
- NIE $18.61
- DNA $5.00
- 52 Week High
- NIE $22.47
- DNA $16.85
- Technical
- Relative Strength Index (RSI)
- NIE 62.81
- DNA 53.69
- Support Level
- NIE $23.71
- DNA $8.21
- Resistance Level
- NIE $24.05
- DNA $13.33
- Average True Range (ATR)
- NIE 0.26
- DNA 0.92
- MACD
- NIE 0.02
- DNA -0.04
- Stochastic Oscillator
- NIE 89.59
- DNA 39.86
About NIE Virtus Equity & Convertible Income Fund of Beneficial Interest
Virtus AllianzGI Equity & Convertible Income Fund is a diversified, closed-end management investment company. The investment objective is to seek total return comprised of capital appreciation, current income, and gains. The fund pursues its objective by investing in a diversified portfolio of equity securities and income-producing convertible securities. Its portfolio of investments comprises different sector investments, such as aerospace and defense, banks, IT services, software, and others.
About DNA Ginkgo Bioworks Holdings Inc.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering: where company provide biological R&D services for customers across a range of industries and Biosecurity: where it provide services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.